Swiss chemical maker Sika's half-year sales fall, miss analyst estimate
The company, which makes products used to strengthen and waterproof walls and floors, said its sales fell 2.7% to 5.68 billion Swiss francs ($7.08 billion) in the six months to June 30.
Analysts had forecast 5.72 billion francs, according to a consensus compiled by Vara.
The company largely attributed the downturn to translation effects of the weaker dollar, which trimmed the revenue from Sika's biggest market - the United States - when converted into Swiss francs.
In local currencies, which takes out the impact of currency fluctuations, Sika's sales grew 1.6%, driven by organic growth and a boost from acquisitions.
The company's core operating profit (EBITDA) fell to 1.07 billion Swiss francs, missing analysts' forecast of 1.09 billion francs.
Sika's results give insight into the health of the broader construction industry, with its chemical additives being used in infrastructure projects such as the Daimer Basha dam in Pakistan and the Gordie Howe International Bridge between the U.S. and Canada.
"Sika is therefore largely unaffected by trade tariffs and can reliably supply its customers, even in challenging market conditions," the company said.
For the full 2025 business year, Sika expects a modest sales increase in local currencies and continues to expect an over-proportional increase in EBITDA and an EBITDA margin of between 19.5% and 19.8%.
($1 = 0.8026 Swiss francs)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
22 minutes ago
- Reuters
Siemens reduces stake in Siemens Healthineers to 71.12%
MUNICH, July 31 (Reuters) - Siemens AG ( opens new tab reduced its stake in medical technology company Siemens Healthineers ( opens new tab by nearly 2 percentage points to 71.12%, according to a regulatory filing. Healthineers' CEO Bernd Montag said earlier this year that the company would welcome a stake reduction by its parent company, calling it "very good" for the long term. "We have repeatedly and clearly stated that we will reduce our stake in Siemens Healthineers as part of the acquisitions of Altair and Dotmatics, without prejudice to any strategic decisions," a Siemens spokesperson told Reuters on Thursday.
Reuters
22 minutes ago
- Reuters
AbbVie lifts annual profit forecast on strong demand for newer immunology drugs
July 31 (Reuters) - AbbVie (ABBV.N), opens new tab raised its 2025 profit forecast on Thursday, after beating Wall Street estimates for second-quarter results on strong sales of its newer immunology drugs Skyrizi and Rinvoq. Shares of the drugmaker rose nearly 3% to $195.03 before the bell. The company is pushing Skyrizi and Rinvoq to counter the drop in sales of Humira, as the once-bestselling drug faces competition from several cheaper biosimilars that began hitting the U.S. market in 2023. "We're entering the second half of the year with substantial momentum," said CEO Robert Michael. Skyrizi recorded quarterly sales of $4.42 billion, beating analysts' average estimate of $4 billion, while Rinvoq sales of $2.03 billion surpassed estimates of $1.97 billion, according to data compiled by LSEG. The North Chicago-based drugmaker has spent more than $20 billion on acquisitions since 2023 as Humira lost patent protection. On Wednesday, Bloomberg News reported that AbbVie is in talks to acquire privately held psychiatric disorder drug developer Gilgamesh Pharmaceuticals in a deal worth about $1 billion. Global sales of arthritis treatment Humira, once the world's best-selling drug, came in at $1.18 billion in the second quarter, missing estimates of $1.45 billion. AbbVie's forecast raise comes on the back of the European Union's framework trade deal with the United States, under which all EU-produced pharmaceuticals entering the U.S. will be subject to a 15% tariff. AbbVie has a significant manufacturing presence in Ireland, where it makes its wrinkle treatment Botox. The company now expects adjusted annual profit per share between $11.88 and $12.08, compared with its previous expectations of $11.67 to $11.87. The company earned quarterly adjusted profit per share of $2.97, compared with estimates of $2.88.
Reuters
23 minutes ago
- Reuters
Trump's watered-down copper tariffs crush Comex premium
BEIJING/LONDON, July 31 (Reuters) - The once-mighty premium U.S. copper enjoyed over the global benchmark swung to a discount on Thursday as markets clawed back months of gains in hours of frenzied trading after President Donald Trump surprised markets with pared-back tariffs. Trump said on Wednesday the United States would impose a 50% tariff on copper pipes and wiring, but the levy fell short of the sweeping restrictions expected and left out copper materials such as ores, concentrates and cathodes. The surprise move dragged down U.S. copper prices more than 20% on the Comex exchange and unwound the premium over the London global benchmark that had grown in recent weeks, with shipments diverted into the U.S. in anticipation of higher domestic prices. "We think the LME flips to a premium in the short term due to excess inventories in the U.S.," Anant Jatia, founder and chief investment officer at Greenland Investment Management, a hedge fund specialising in commodity arbitrage trading, told Reuters. "Over time Comex moves back to a premium as inventories draw and downstream tariffs leave a sustained U.S. premium." U.S. September Comex copper futures were last down 22% to $4.359 a lb or $9,610 per metric ton on Thursday, meaning a discount over LME copper of $20 a ton. This compares with last week's premium of $3,000. Benchmark LME copper fell 0.7% to $9,630 a ton. Months of meaty premiums had sucked in enormous volumes of copper from around the world since Trump first flagged the possibility of tariffs in February. As recently as a few weeks ago, traders were still redirecting cargoes to the United States in a rush to get copper into the country before the tariffs. Trump's unexpected pivot now raises the question of whether some of that stockpile might be re-exported. Macquarie estimated earlier this month it would take nine months of normal consumption just to run down the inventories built up in the first half of the year. Goldman Sachs said in a note on Thursday that Trump's threat to potentially impose tariffs on refined copper in 2027 would keep U.S. and global prices near parity and limit any large scale re-exporting. Trump first teased the tariff in early July, implying that it would apply to all types of the red metal, ranging from cathodes produced by mines and smelters to wiring and other finished products. Yet in a proclamation released by the White House, the administration said the tariff starting this Friday will apply only to pipes, tubes and other semi-finished copper products, as well as products that copper is heavily used to manufacture, including cable and electrical components.
